|Awarded On||February 15, 2023|
|Title||A Novel Therapeutic Strategy Targeting Pancreatic Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Wantong Yao|
*Pending contract negotiation
Pancreatic cancer has the lowest survival rate among human cancer types and is one of the most resistant cancers to traditional therapies, such as chemotherapy, radiotherapy and targeted therapy. Immunotherapy has had remarkable efficacy in many cancer types but has not gained much success in pancreatic cancer. Notably, nearly every human pancreatic cancer contains activating mutations in the KRAS gene, which drive the development and maintenance of the disease. Thus, mKRAS has been one of the most desirable drug targets in the pharmaceutical industry. After decades of failure, inhibitors specifically targeting KRAS have recently entered clinical trials and demonstrated promising clinical b...